The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
Michaela Liedtke
Hematologist, Medical oncologist, Multiple myeloma specialist, Leukemia specialist
Associate Professor of Medicine (Hematology) at the Stanford University Medical Center
- 875 Blake Wilbur Drive
- Clinic F
- Palo Alto , CA 94304
- Phone: 650-498-6000
- 300 Pasteur Drive
- 2nd Floor, Room A260
- Stanford , CA 94305
- Phone: 650-725-6186
Practice Areas
Professional Education
- Residency: Albert Einstein College of Medicine Office of the Registrar (2002) NY
- Medical Education: Medizinische Hochschule Hannover (1996) Germany
- Fellowship: Memorial Sloan-Kettering Cancer Center (2004) NY
- Board Certification: Hematology, American Board of Internal Medicine (2005)
- Fellowship: Stanford University Medical Center (2005) CA
Honors & Awards
- Fellowship Award, Lymphoma Research Foundation (2004)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Research grant, Hope Street Kids Foundation (2006)
- Translational Research Award, Doris Duke Foundation (2004)
- Translational Research Award, Stanford Department of Medicine (2011)
- Young Investigator Award, ASCO (2008)
Administrative Appointments
- Medical Director, Stanford Adolescent and Young Adult Program (2015 - Present)
- Member, Stanford Amyloid Center (2010 - Present)
- Member Leukemia Committee, Southwest Oncology Group (2011 - Present)
Publications
-
A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., … Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808–4815. -
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909–913. -
Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85. -
-
-
-
-
-
-
-
The Transcription Factor Encyclopedia
Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., … Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3).
-
-
-
Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands).
-
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96.
-
Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11–17.
-
-
-
-
-
Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase
Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889–1892.
-
-
Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45–S46.
-
-
Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression.
Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. American Journal of Surgical Pathology, 38(9), 1298–1304.
-
Effects of serum and plasma matrices on multiplex immunoassays.
Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. Immunologic Research, 58(2-3), 224–33.
-
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715–24.
-
-
-
-
Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma
Hansmann, L., Blum, L., Ju, C.-H., Liedtke, M., Robinson, W. H., & Davis, M. M. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. CANCER IMMUNOLOGY RESEARCH, 3(6), 650–60.
-
-
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2015). Multiple Myeloma, Version 2.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1398–1435.
-
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59.
-
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., … Liedtke, M. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology , 34(10), 1097–1103.
-
-
-
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., … Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740–53.
-
Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2016). Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(4), 389–400.
-
Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., … Kumar, R. (2017). Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(2), 230-?
-
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia.
-
-
-
NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY
Liedtke, M., Comenzo, R., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., … Gertz, M. (2017). NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 825.
-
NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response
Liedtke, M. M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response. EUROPEAN JOURNAL OF HEART FAILURE, 19, 441.
-
A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., … Durie, B. G. M. (2014). A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. BLOOD, 124(21).
-
Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016
Maurer, M., Lousada, I., Hanna, M., Ruberg, F., Mohty, D., Dispenzieri, A., … Grogan, M. (2017). Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 24, 165–66.
-
Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2015). Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. BLOOD, 126(23).
-
The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.
Liedtke, M., Merlini, G., Landau, H. J., Comenzo, R., Seldin, D. C., Weiss, B. M., … Gertz, M. A. (2015). The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
-
NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study
Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2016). NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study. EUROPEAN HEART JOURNAL, 37, 220.
-
-
NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., … Shead, D. A. (2018). NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(1), 11–20.
-
-
NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response
Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response. ONCOLOGY RESEARCH AND TREATMENT, 40, 34–35.
-
NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY
Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, Weiss, B. M., Zonder, J. A., … Liedtke, M. (2017). NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 22(3), 289–90.
-
Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE
Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2018). Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE. CANCER, 124(8), 1722–32.
-
Novel therapeutic approaches for AL amyloid
Liedtke, M. (2017). Novel therapeutic approaches for AL amyloid. ONCOLOGY RESEARCH AND TREATMENT, 40, 194.
-
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., … Advani, A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. BLOOD ADVANCES, 1(15), 1167–80.
-
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. BLOOD, 130(7), 900–902.
-
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response
Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., … Advani, A. S. (2018). Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. LEUKEMIA & LYMPHOMA, 59(2), 363–71.
-
-
Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.
Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology.
-
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., … Baz, R. (2018). Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 182(2), 231–44.
-
-
Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis
Yen, T., Chen, F., Witteles, R., Liedtke, M., & Nguyen, L. A. (2017). Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112, S240.
-
-
-
-
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Jabbour, E., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2019). Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology.
-
-
Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse
Aleshin, A., Durruthy-Durruthy, R., Corces, M. R., Stafford, M., Liedtke, M., Medeiros, B. C., … Majeti, R. (2018). Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse. BLOOD, 132.
-
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia.
-
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer.
-
-
-
-
-
-
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, May 2019
I had a very positive experience with all care providers, felt taken care of and given information for my understanding.
SHC Patient, Apr 2019
Dr. Liedtke is amazing; The resident fellows have been amazing too. Very professional and knowledgeable.
SHC Patient, Mar 2019
Live in N. Nevada. Love Dr. Liedtke. I wish we could see her every month!
SHC Patient, Mar 2019
I have often referred her to new people in my surgery group.
SHC Patient, Feb 2019
All Stanford docs I've had the last 15 yrs. have been excellent!
SHC Patient, Feb 2019
Excellent.
SHC Patient, Feb 2019
Dr. Liedtke was great!
SHC Patient, Oct 2018
All good.
SHC Patient, Oct 2018
Dr. Liedtke is excellent, the MD doing the initial consult was quite good as well.
SHC Patient, Oct 2018
I seen Dr. Greg Kaufman first the Dr. Liedtke. Thy were both amazing, I felt very comfortable with both. Dr. Liedtke was very nice and she made me feel like she really cared about me & my situation.
SHC Patient, Aug 2018
Found Dr. Liedtke and her asst. more than caring, knowledgeable and compassionate. I was so honored to have a doctor of her repute to work with me. She gave me hope, I'll never forget her and my experience with her.
SHC Patient, Aug 2018
Excellent experience.
SHC Patient, Jun 2018
Very good.
SHC Patient, Jun 2018
I was thoroughly pleased with Dr. Liedtke's explanation, I feel so blessed that she is my care provider.
SHC Patient, Jun 2018
Explained everything and answered all our questions and concerns. Very patient and understanding. A very caring person.
SHC Patient, May 2018
Dr. Liedtke and her resident fellow, Greg Kaufmann were amazing - so put me at ease - this was my first visit to Stanford and I was very impressed with both doctors.
SHC Patient, May 2018
Outstanding! Very thorough.
SHC Patient, Mar 2018
Every staff member seems to exert the same respect & courtesy to my wife & while we are there.
SHC Patient, Mar 2018
Dr. Michaela Liedtke is a great asset to your hospital, also Dr. Ronald Witteles. THANK YOU.
SHC Patient, Mar 2018
She is always awesome never rushes.
SHC Patient, Mar 2018
Dr. Liedke is a great doctor. Shows concern compassion in clinic encounter each and every visit.
SHC Patient, Feb 2018
We LOVE Dr. Liedtke.
SHC Patient, Nov 2017
She is excellent!
SHC Patient, Nov 2017
Dr. M. Liedtke, like Dr. LaPorte and Goldstein before her all excellent. Also, she works well with my local physician - coordinating my care.
SHC Patient, Nov 2017
My visit was a very good one.
SHC Patient, Oct 2017
Listened well to my questions/concerns. Explained thoroughly.
SHC Patient, Oct 2017
God bless you always I have had a very good experience on being treated by you.
SHC Patient, Sep 2017
Always very good.
SHC Patient, Sep 2017
They met all my expectations.
SHC Patient, Sep 2017
Reassurance on care needed given.
SHC Patient, Aug 2017
I was so impressed with Dr. Liedtke, her fellow, and everything else about Stanford that I've decided to use Stanford instead of UCSF.
SHC Patient, Jul 2017
She has taken the time to call me at home with suggestions on my care.
SHC Patient, May 2017
The best ever!!
SHC Patient, Apr 2017
Empathy very evident... reassuring experience.
SHC Patient, Mar 2017
I feel I have received outstanding care form Dr. Liedtke.
SHC Patient, Feb 2017
Good.
SHC Patient, Feb 2017
Good.
SHC Patient, Jan 2017
Excellent care and concern shown by Dr. Liedtke and Misty Mahaffey (NP) at my clinic appointment.
SHC Patient, Jan 2017
Dr. Liedtke is a very kind, caring, and a great doctor!
SHC Patient, Dec 2016
Love my oncologist, palliative. They are so kind.
SHC Patient, Nov 2016
All good.
SHC Patient, Nov 2016
They had me... with my questions that they were doing thanks.
SHC Patient, Nov 2016
All very good.
SHC Patient, Nov 2016
I have been very happy with the care I have received from Dr. Liedtke.
SHC Patient, Nov 2016
All very nice.
SHC Patient, Oct 2016
She is very respectful of my opinion. She is a very humble person, which is unusual in a MD.
SHC Patient, Oct 2016
Excellent svc.!
SHC Patient, Oct 2016
Dr. Liedtke is a fantastic doctor. The best I've ever seen. She explain everything to me and my family. It shows that she really cares -
SHC Patient, Sep 2016
Dr. Liedtke is the best - caring, informative and knowledgeable. I would recommend her to everybody.
SHC Patient, Sep 2016
Dr. Liedtke is genuinely caring - and competent - a combination that is exceptional.
SHC Patient, Aug 2016
She took the time to provide a detailed and clear explanation regarding my condition, the possibilities and her plan of action. Dr. Liedtke was EXCELLENT I have high confidence in this doctor.
SHC Patient, Aug 2016
Love Dr. Liedtke.
SHC Patient, Jul 2016
Dr. Liedtke is the best. She explains and shows concern for my health. I have complete confidence in her.
SHC Patient, Jul 2016
Dr. Liedtke is wonderful - feel very fantastic to have her as my specialist.
SHC Patient, Jul 2016
All very good.
SHC Patient, Jul 2016
We really love Dr. Liedtke. She is so caring and knowledgeable. We are lucky to have her as a provider. It is hard to find a doctor like her.
SHC Patient, Jun 2016
Outstanding physician for my particular disease.
SHC Patient, Jun 2016
Dr. Liedtke is a great communicator and inspires my confidence in her. I have a lot of questions and she listens and answers them all she is fully responsive to email communications and volunteered her work e-mail address.
SHC Patient, May 2016
Dr. Liedtke, PA, and NP were very knowledgeable. I could ask for any more professional staff to assist me.
SHC Patient, May 2016
I feel so fortunate to have Michaela Liedtke as my myeloma specialist. She answered questions, listens, is informative and caring - truly top notch - could not be in better hands.
SHC Patient, Apr 2016
Excellent doctor always concerned for me.
SHC Patient, Apr 2016
My experience with the nurses & doctors was great.
SHC Patient, Mar 2016
Good.
SHC Patient, Mar 2016
I feel very fortunate and grateful to be cared for by Dr Liedtke
SHC Patient, Mar 2016
Nice and very kind.
SHC Patient, Mar 2016
I have the utmost confidence in Dr. Liedtke.
SHC Patient, Mar 2016
Love everyone at Stanford they are kind and careing and very smart! I would not be alive if I didn't have Stanford to go to that's why I drive four hours to get there!
SHC Patient, Feb 2016
Dr Liedtke has been my doctor for eight years. She is very helpful, understanding, knowledgeable about my disease. My pain, my feelings and knows what treatment I need. She is the same the first time I saw her and until now. I am confident that she can cure me.
SHC Patient, Feb 2016
Excellent! Dr Liedtke is a great communicator. She always understands exactly what I'm asking and gives precise, understandable answers. She has never appeared rushed with me, giving all the time I need to ask questions. She is also very kind.
SHC Patient, Jan 2016
She was an awesome doctor. I was lucky and blessed to have her. She was so kind and considerate. A confident and gentle spirit and a great leader for her staff.
SHC Patient, Jan 2016
I have the highest degree of admiration and respect for Dr. Liedtke.
SHC Patient, Dec 2015
Dr. Liedtke is the best doctor I have ever had. I have seen many, but she by far is the very best. I am very blessed to have her.
SHC Patient, Nov 2015
Dr. Liedtke is very good at responding to messages with questions or concerns I might have between regular appointments. This is all done electronically through the website with no need for phone calls.
SHC Patient, Nov 2015
Fantastic.
SHC Patient, Apr 2015
Thank you Dr Liedtke
SHC Patient, Apr 2015
Always a good experience Dr. Liedtke is very caring and concerned; she always explains my condition in a way I understand. I really like Dr. Liedtke. She's a sweetheart!!!
SHC Patient, Apr 2015
Very pleased with my doctor - Excellent care - Dr. Liedtke.
SHC Patient, Mar 2015
Have been very impressed with Dr. Liedtke in all my dealings with her.
SHC Patient, Jan 2015
Dr. Liedtka listens to you and ask questions. She is understanding of your needs. Being a scrub nurse, I do not do things normally in my medical history. She understands that. She is great.
SHC Patient, Jan 2015
Impressive MD's!
SHC Patient, Jan 2015
No bad experience.
SHC Patient, Dec 2014
Dr. Liedtke is saving my life!
SHC Patient, Oct 2014
Dr. Liedtke had not seen us before, so she was a little surprised, but did a great job.
SHC Patient, Aug 2014
She's a sweetheart - We're very blessed to be in her care.
SHC Patient, Apr 2014
I am very confident with Dr. M Liedtke. Her name is outstanding.
SHC Patient, Jan 2014
Dr. Liedtke is excellent.
SHC Patient, Dec 2013
Good.
SHC Patient, May 2019
I had a very positive experience with all care providers, felt taken care of and given information for my understanding.
SHC Patient, Apr 2019
Dr. Liedtke is amazing; The resident fellows have been amazing too. Very professional and knowledgeable.
SHC Patient, Mar 2019
Live in N. Nevada. Love Dr. Liedtke. I wish we could see her every month!
SHC Patient, Mar 2019
I have often referred her to new people in my surgery group.
SHC Patient, Feb 2019
All Stanford docs I've had the last 15 yrs. have been excellent!
SHC Patient, Feb 2019
Excellent.
SHC Patient, Feb 2019
Dr. Liedtke was great!
SHC Patient, Oct 2018
All good.
SHC Patient, Oct 2018
Dr. Liedtke is excellent, the MD doing the initial consult was quite good as well.
SHC Patient, Oct 2018
I seen Dr. Greg Kaufman first the Dr. Liedtke. Thy were both amazing, I felt very comfortable with both. Dr. Liedtke was very nice and she made me feel like she really cared about me & my situation.
SHC Patient, Aug 2018
Found Dr. Liedtke and her asst. more than caring, knowledgeable and compassionate. I was so honored to have a doctor of her repute to work with me. She gave me hope, I'll never forget her and my experience with her.
SHC Patient, Aug 2018
Excellent experience.
View All 87 Patient Comments »